title: FPIN’s clinical inquiries. Medications for weight loss in patients with type 2 diabetes mellitus.
authors.affiliation: University of Arkansas for Medical Sciences, Pine Bluff, AR, USA. lkachowski@uams.edu
authors.forename: Larisa
authors.initials: L
authors.lastname: Kachowski
authors.forename: Darrell R
authors.initials: DR
authors.lastname: Over
authors.forename: Kefeng
authors.initials: K
authors.lastname: Qiu
mesh_terms: D019440:Anti-Obesity Agents / Q000627:therapeutic use*; D003503:Cyclobutanes / Q000009:adverse effects / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2; D005473:Fluoxetine / Q000009:adverse effects / Q000627:therapeutic use; D005632:Fructose / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D007783:Lactones / Q000009:adverse effects / Q000627:therapeutic use; D000077403:Orlistat; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D000077236:Topiramate
chemical_list: D019440:Anti-Obesity Agents; D003503:Cyclobutanes; D005473:Fluoxetine; D005632:Fructose; D007783:Lactones; D000077403:Orlistat; D017367:Selective Serotonin Reuptake Inhibitors; D000077236:Topiramate; C058254:sibutramine